Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: A prospective study

Journal of Hepatology

Volumn 39, Issue 4, 2003, Pages 614-619

  Ryu, Soo Hyung ^a   Chung, Young Hwa ^a   Choi, Min Hee ^a   Kim, Jeong A ^a   Shin, Jung Woo ^a   Jang, Myoung Kuk ^a   Park, Neung Hwa ^a   Lee, Han Chu ^a   Lee, Yung Sang ^a   Suh, Dong Jin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Durability; HBeAg; Hepatitis B virus; Lamivudine; Seroconversion

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; HYBRIDIZATION; IMMUNOASSAY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RELAPSE; SENESCENCE; SEROCONVERSION; VIROLOGY; VIRUS REACTIVATION;

EID: 12444287949     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(03)00394-5     Document Type: Article

References (25)

1. Doong S-L, Tsai C-H, Schinazi RF, Liotta DC, Cheng Y-C. Inhibition of the replication of hepatitis B virus in vitro by 2′, 3′ -dideoxy-3′-thiacytidine and related analogues. Proc Natl Acad Sci USA 1991;88:8495-8499.
2. Chang CN, Skalski V, Zhou JH, Cheng Y-C. Biochemical pharmacology of (+) and (′) 2′, 3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agents. J Biol Chem 1992;267:22414-22420.
3. Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-1661.
4. Lai C-L, Chien R-N, Leung NWY, Chang T-T, Guan R, Tai D-I, Ng K-Y, et al. The Asia Hepatitis Lamivudine Study Group. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998;339:61-68.
5. Dienstag JL, Schiff ER, Mitchell M, Casey Jr DE, Gitlin N, Lissoos T, Gelb LD, et al. Extended lamivudine retreatment for chronic hepatitis: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999;30:1082-1087.
6. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HWL, Goodman Z, Crowther L, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-1263.
7. Schiff E, Cianciara J, Karayalcin S, Kowdley K, Woessner M, McMullen S, Pearce M, et al. the International Lamivudine Investigator Group. Durable HBeAg and HBsAg seroconversion after lamivudine for chronic hepatitis B (abstr). J Hepatol 2000;32:99.
8. Song B-C, Suh DJ, Lee HC, Chung Y-H, Lee YS, Hepatitis Be. antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32:803-806.
9. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996;93:4398-4402.
10. Zeuzem S, de Man RA, Honkoop P, Roth WK, Schalm SW, Schmidt JM. Dynamics of hepatitis B virus infection in vivo. J Hepatol 1997;27:431-436.
11. Baker BL, Di Bisceglie AM, Kaneko S, Miller R, Feinstone SM, Waggoner JG, Hoofnagle JH, Determination of hepatitis B virus DNA in serum using the polymerase chain reaction: clinical significance and correlation with serological and biochemical markers. Hepatology 1991;13:632-636.
12. Kaneko S, Miller RH, Di Bisceglie AM, Feinstone SM, Hoofnagle JH, Purcell RH. Detection of hepatitis B virus DNA in serum by polymerase chain reaction. Application for clinical diagnosis. Gastroenterology 1990;99:799-804.
13. Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225-1241.
14. Core Working Party For Asia-Pacific Consensus On Hepatitis B and C, Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. J Gastroenterol Hepatol 2000;15:825-841.
15. Chang T-T, Lai C-L, Liaw Y-F, Guan R, Lira S-G, Lee CM, Ng K-Y, et al. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV patients treated with lamivudine for 4 years (Abstract(. Antiviral Ther 2000;5:44.
16. Lee KM, Cho SW, Kim SW, Kim HJ, Hahm KB, Kim JH. Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion. J Viral Hepat 2002;9:208-212.
17. Wu T-T, Coates L, Aldrich CE, Summers J, Mason WS. In hepatocytes infected with duck hepatitis B virus, the template for viral RNA synthesis is amplified by an intracellular pathway. Virology 1990;175:255-261.
18. Liaw Y-F, Leung NWY, Chang T-T, Guan R, Tai D-I, Ng K-Y, Chien R-N, et al. The Asia Hepatitis Lamivudine Study Group. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000;119:172-180.
19. Leung NWY, Lai C-L, Chang T-T, Guan R, Lee C-M, Ng K-Y, Lira S-G, et al. The Asia Hepatitis Lamivudine Study Group. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-1532.
20. Yuen M-F, Sablon E, Hui C-K, Yuan H-J, Decraemer H, Lai C-L. Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy. Hepatology 2001;34:785-791.
21. Park NH, Joo KR, Kim DH. The effect of lamivudine therapy for chronic liver disease due to hepatitis B virus infection. Korean J Hepatol 2001;7:77-89.
22. Song B-C, Sub DJ, Lee HC, Chung Y-H, Lee YS. Lamivudine therapy for chronic hepatitis B: efficacy, predictive factors for response and relapse rate after treatment. Korean J Med 2000;58:386-391.
23. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, et al. The Lamivudine Precore Mutant Study Group. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999;29:889-896.
24. Santantonio T, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. J Hepatol 2000;32:300-306.
25. Zoulim F, Trepo C. Is lamivudine effective on precore/core promoter mutants of hepatitis B virus? Hepatology 2000;32:1172-1174.